Advertisement

Topics

Serono Laboratories (UK) Limited Company Profile

16:06 EDT 26th September 2017 | BioPortfolio

We are one of the world’s top three biotechnology companies, with revenues of USD 1.38 billion (2001).

We currently focus on three core therapeutics areas:



Reproductive Health Multiple Sclerosis

Growth & Metabolism



We are also investing strongly in the future, as expressed by our New Therapeutic Areas.



Global reach

We operate in 45 countries and have sales in over 100 countries.

Location

Bedfont Cross, Stanwell road
Feltham
Middlesex
TW14 8NX
United Kingdom

Contact

Phone: +44-20-8818-7200
Fax: +44-20-8818-7222


News Articles [385 Associated News Articles listed on BioPortfolio]

Contrasting IDEXX Laboratories

IDEXX Laboratories and Heska Corporation are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, di...

Enterome to move its research laboratories

Enterome, a pioneer of innovative therapies for microbiome-related diseases announced that the Company is moving its research laboratories to Genopole, a leading biocluster dedicated to biotechnology ...

Zacks: Brokerages Anticipate Impax Laboratories Inc (IPXL) Will...

Wall Street analysts forecast that Impax Laboratories Inc will post $196.18 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Impax Laboratories'...

EMD Serono To Present Data Highlighting Investigational Cladribine Tablets At

  Life Sciences Jobs   ...

Analyzing Impax Laboratories

Pfizer and Impax Laboratories are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional owner...

EMD Serono to Present Data Highlighting Investigational Cladribine Tablets at CMSC 2017

ROCKLAND, Mass., May 25, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced 14 presentations, including ...

$0.14 EPS Expected for Impax Laboratories, Inc. (IPXL) This Quarter

Analysts expect Impax Laboratories, Inc. to report earnings per share of $0.14 for the current fiscal quarter, according to Zacks . Four analysts have provided estimates for Impax Laboratories' ea...

Zacks: Analysts Anticipate Impax Laboratories Inc (IPXL) to Announce $0.13 EPS

Equities analysts expect that Impax Laboratories Inc will post earnings per share of $0.13 for the current quarter, according to Zacks Investment Research . Four analysts have made estimates for Impax...

PubMed Articles [194 Associated PubMed Articles listed on BioPortfolio]

Avelumab: First Global Approval.

Avelumab (Bavencio(®)) is an intravenously administered programmed cell death ligand-1-blocking human antibody initially developed by EMD Serono Inc. (the biopharmaceutical division of Merck KGaA, Da...

Project management: importance for diagnostic laboratories.

The constraints applied on diagnostic laboratories to improve both quality and productivity together with personal shortages incite laboratory managers to constantly optimize the laboratory workflows,...

Cancer incidence in female laboratory employees: extended follow-up of a Swedish cohort study.

Work in chemical laboratories is associated with exposure to chemicals, of which some are known or suspected carcinogens. A cohort study of laboratory workers in Stockholm followed until 1992 showed a...

This Is not Participatory Design - A Critical Analysis of Eight Living Laboratories.

Design of Health Technology for elderly and care personnel has a high priority because of a severe increase of elderly citizens in need of health care combined with a decrease of resources in the heal...

Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories.

Genetic tests of the cancer predisposition genes BRCA1 and BRCA2 inform significant clinical decisions for both physicians and patients. Most uncovered variants are benign, and determining which few a...

Clinical Trials [245 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.

Purpose of the study is the comparative evaluation of the clinical efficacy and of the general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs Gonal-F® Ser...

Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Darmstadt, Germany, June 17 2010 - Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome ...

A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal

The objectives of this study are to compare the efficacy and safety of Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) vs. Clotrimazole Troche/ Lozenge...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition

The objective of this study was to compare the single-dose relative bioavailability of Dr. Reddy's Laboratories, Ltd. and Merck & Co. (Propecia®) 1 mg finasteride tablets under fed condi...

Companies [1039 Associated Companies listed on BioPortfolio]

Merck Serono

Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono ...

Serono Laboratories Incorporated

We develop innovative products to fight debilitating diseases and improve the lives of our patients.We aspire to create an environment that enables our people to excel and innovate and to contribute t...

Serono Inc.

Serono is a global biotechnology leader with over 4,750 employees and worldwide revenues of USD 2,586.4 million in the year 2005. We have eight biotechnology products on the market and currently more ...

Serono Laboratories (UK) Limited

We are one of the world’s top three biotechnology companies, with revenues of USD 1.38 billion (2001).We currently focus on three core therapeutics areas:Reproductive Health Multiple Sclerosis Growt...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

More Information about "Serono Laboratories (UK) Limited" on BioPortfolio

We have published hundreds of Serono Laboratories (UK) Limited news stories on BioPortfolio along with dozens of Serono Laboratories (UK) Limited Clinical Trials and PubMed Articles about Serono Laboratories (UK) Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Serono Laboratories (UK) Limited Companies in our database. You can also find out about relevant Serono Laboratories (UK) Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...


Corporate Database Quicklinks



Searches Linking to this Company Record